Intensifying the mAb capture step for cost-efficient processing

In this presentation we describe and evaluate various strategies for the monoclonal antibody (mAb) capture step. We look at factors to consider when choosing a strategy, including the mode of operation and the main priorities for the capture step, such as productivity, cost, or process time. We also discuss opportunities presented by the recent introduction of high-capacity protein A resins and explore how and when different protein A resins can be beneficial.

Learn more about our protein A resins:
https://www.cytivalifesciences.com/solutions/bioprocessing/products-and-solutions/downstream-bioprocessing/protein-a-chromatography-solutions

Speaker
Eva Heldin